| 血清特异性烯醇化酶、胃泌素释放肽前体在小细胞肺癌诊断和治疗效果评价中的作用 |
| |
| 引用本文： | 张婷素,袁春樱,邱海江,屠小龙.血清特异性烯醇化酶、胃泌素释放肽前体在小细胞肺癌诊断和治疗效果评价中的作用[J].中华全科医学,2019,17(6):959. |
| |
| 作者姓名： | 张婷素 袁春樱 邱海江 屠小龙 |
| |
| 作者单位： | 1. 宁波市中医医院肿瘤科, 浙江 宁波 315010; |
| |
| 基金项目： | 浙江省医学会临床科研基金项目(2018ZYC-A109) |
| |
| 摘 要： | 目的 分析神经元特异性烯醇化酶(NSE)和胃泌素释放肽前体(ProGRP)在小细胞肺癌(SCLC)诊断和治疗效果评价中的应用价值。 方法 回顾性分析2016年1月—2018年6月在宁波市中医医院首次确诊并化疗的52例小细胞肺癌(SCLC)患者和70例非小细胞肺癌(NSCLC)患者的临床资料，患者血清中NSE和ProGRP水平分别采用酶联免疫吸附测定法和化学发光法进行检测。 结果 治疗前SCLC组患者的血清NSE水平高于NSCLC组，差异有统计学意义(P<0.001)，广泛期(ED)患者血清NSE水平高于局限期(LD)患者，差异有统计学意义(P<0.001)；SCLC组患者的血清ProGRP水平高于NSCLC组，差异有统计学意义(P<0.001)，ED患者血清ProGRP水平高于LD患者，差异有统计学意义(P<0.001)。经过2个周期化疗后，52例SCLC患者中有效组39例，无效组13例，有效组患者治疗后的血清NSE水平低于治疗前，差异有统计学意义(P<0.001)；无效组患者治疗前后血清NSE水平差异无统计学意义(P>0.05)；有效组患者治疗后的血清ProGRP水平低于治疗前，差异有统计学意义(P<0.001)；无效组患者治疗后血清ProGRP水平高于治疗前，差异有统计学意义(P<0.05)。 结论 血清NSE和ProGRP水平升高可能有助于SCLC患者和NSCLC患者的鉴别诊断，血清NSE和ProGRP水平可作为SCLC分期的辅助依据。ProGRP在监测SCLC病情变化、评估疗效等方面可能较NSE有更高的应用价值。
|
| 关 键 词： | 神经元特异性烯醇化酶 胃泌素释放肽前体 小细胞肺癌 鉴别诊断 |
| 收稿时间： | 2019-01-03 |
The role of serum NSE and proGRP in the diagnosis and treatment of small cell lung cancer |
| |
| Affiliation: | Department of Oncology, Ningbo Traditional Chinese Medicine Hospital, Ningbo, Zhejiang 315010, China |
| |
| Abstract: | Objective To analyze the value of neuron-specific enolase (NSE) and pro-gastrin-releasing peptide (proGRP) in the diagnosis and treatment of small cell lung cancer (SCLC). Methods The clinical data of 52 patients with SCLC and 70 patients with non-small cell lung cancer (NSCLC) who were first diagnosed and treated in our hospital from January 2016 to June 2018 were retrospectively analyzed. The serum levels of NSE and proGRP were detected by ELISA and chemiluminescence respectively. Results Before treatment, the serum NSE level in SCLC group was higher than that in NSCLC group (P<0.001), the serum NSE level in ED group was higher than that in LD group (P<0.001), the serum ProGRP level in SCLC group was higher than that in NSCLC group (P<0.001), and the serum ProGRP level in ED group was higher than that in LD group (P<0.001). After 2 cycles of chemotherapy, there were 39 cases in the effective group and 13 cases in the ineffective group. The level of serum NSE in the effective group after treatment was lower than that before treatment, and the difference was statistically significant(P<0.001)|the level of serum NSE in the ineffective group before and after treatment had no statistical significance(P>0.05)|the level of serum ProGRP in the effective group after treatment was lower than that before treatment, and the difference was statistically significant(P<0.001)|the level of serum ProGRP in the ineffective group after treatment was higher than that before treatment, and the difference was statistically significant(P<0.05). Conclusions The elevated levels of serum NSE and ProGRP may be helpful for the differential diagnosis between SCLC patients and NSCLC patients. Serum levels of NSE and ProGRP can be used as an auxiliary basis for SCLC staging. ProGRP may have higher application value than NSE in monitoring the changes of SCLC and evaluating the therapeutic effect. |
| |
| Keywords: | |
|
| 点击此处可从《中华全科医学》浏览原始摘要信息 |
|
点击此处可从《中华全科医学》下载全文 |
|
